Revenio Group Corporation: Mikko Moilanen starts as the CEO of Revenio Group Corporation today
Stock Exchange Release August 5, 2019, at 10.00 am EET
MIKKO MOILANEN STARTS AS THE CEO OF REVENIO GROUP TODAY
M.Sc. (EE) Mikko Moilanen, will start in his position as the CEO of Revenio Group Corporation today. The previous CEO Timo Hildén continues to lead the integration work of CenterVue acquisition.
Mikko Moilanen has earlier worked as the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, as the CEO of Suunto Oy and he has held several international management positions in Nokia Plc.
“During the summer, I have had the pleasure of getting to know Revenio and its subsidiaries and meeting some key persons. I am very impressed with the professionalism, accuracy and quality of which the Group's business operations are conducted. The companies are strongly positioned to excel in the health technology industry, which offers growth opportunities. I am very pleased that I can now study the role to the full; to meet people and hear their views. The time for future step marks is after careful study,” says Mikko Moilanen, CEO of Revenio Group Corporation.
For further information, please contact:
Chairman of the Board Pekka Rönkä, tel. +358 40 826 4356
Mikko Moilanen, tel. +358 400 742 559
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Picture: Mikko Moilanen
The Revenio Group in brief
Revenio is a globally operating health technology corporation and a global leader in ophthalmic products.
The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
The common denominator of Revenio's business is patient driven screening, monitoring and the global need for cost savings in healthcare through preventive healthcare. Revenio seeks strong growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The objective is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of Group is on the early detection and the management of sight-threatening pathologies such as Glaucoma, Diabetic Retinopathy and Macular Degeneration. Revenio Research, in turn, focuses on the commercialization of systems supporting the diagnosis and treatment of skin cancer and asthma.
In 2018, the Revenio Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.